Maravai Lifesciences Holdings Stock Today
| MRVI Stock | USD 2.38 0.11 4.85% |
PerformanceWeak
| Odds Of DistressAverage
|
Maravai Lifesciences is trading at 2.38 as of the 26th of June 2025. This is a 4.85 percent increase since the beginning of the trading day. The stock's open price was 2.27. Maravai Lifesciences has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 28th of March 2025 and ending today, the 26th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of November 2020 | Category Healthcare | Classification Health Care |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Maravai LifeSciences Holdings, Inc. The company has 143.98 M outstanding shares of which 13.67 M shares are now shorted by private and institutional investors with about 7.4 trading days to cover. More on Maravai Lifesciences Holdings
Moving together with Maravai Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Maravai Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Bernd Brust | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Pharmaceutical Products, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMaravai Lifesciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Maravai Lifesciences' financial leverage. It provides some insight into what part of Maravai Lifesciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maravai Lifesciences Holdings (MRVI) is traded on NASDAQ Exchange in USA. It is located in 10770 Wateridge Circle, San Diego, CA, United States, 92121 and employs 580 people. Maravai Lifesciences is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 829.33 M. Maravai Lifesciences conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 143.98 M outstanding shares of which 13.67 M shares are now shorted by private and institutional investors with about 7.4 trading days to cover.
Maravai Lifesciences Holdings currently holds about 617.45 M in cash with 7.46 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Maravai Lifesciences Probability Of Bankruptcy
Ownership AllocationMaravai Lifesciences maintains a total of 143.98 Million outstanding shares. The majority of Maravai Lifesciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Maravai Lifesciences Holdings to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Maravai Lifesciences. Please pay attention to any change in the institutional holdings of Maravai Lifesciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Maravai Ownership Details
Maravai Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 2.5 M | |
| Ameriprise Financial Inc | 2025-03-31 | 2.5 M | |
| Two Sigma Advisers, Llc | 2025-03-31 | 2.2 M | |
| Deutsche Bank Ag | 2025-03-31 | 2.1 M | |
| Ubs Group Ag | 2024-12-31 | 2 M | |
| Point72 (difc) Ltd | 2025-03-31 | 1.6 M | |
| Systematic Financial Management Lp | 2025-03-31 | 1.5 M | |
| Two Sigma Investments Llc | 2025-03-31 | 1.4 M | |
| Goldman Sachs Group Inc | 2025-03-31 | 1.4 M | |
| Gtcr Llc | 2025-03-31 | 20.2 M | |
| 12 West Capital Management Lp | 2025-03-31 | 12.5 M |
Maravai Lifesciences Historical Income Statement
Maravai Stock Against Markets
Maravai Lifesciences Corporate Management
| Kurt Oreshack | General VP | Profile | |
| Christine Dolan | Executive Technologies | Profile | |
| Brian Neel | Chief Production | Profile | |
| Peter Leddy | Executive Officer | Profile | |
| Christopher Benoit | Executive Enzymes | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.33) | Earnings Share (1.17) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets |
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.